Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

Por Dowsett, Mitch, Procter, Marion, McCaskill-Stevens, Worta, de Azambuja, Evandro, Dafni, Urania, Rueschoff, Josef, Jordan, Bruce, Dolci, Stella, Abramovitz, Mark, Stoss, Oliver, Viale, Giuseppe, Gelber, Richard D., Piccart-Gebhart, Martine, Leyland-Jones, Brian
Publicado em 2009

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Por Van Cutsem, Eric, Bang, Yung-Jue, Feng-yi, Feng, Xu, Jian M., Lee, Keun-Wook, Jiao, Shun-Chang, Chong, Jorge León, López-Sanchez, Roberto I., Price, Timothy, Gladkov, Oleg, Stoss, Oliver, Hill, Julie, Ng, Vivian, Lehle, Michaela, Thomas, Marlene, Kiermaier, Astrid, Rüschoff, Josef
Publicado no Gastric Cancer (2014)